Pathway Genomics has added the Illumina MiSeqDx to its fleet of next-generation sequencing systems.

 

 

 

Designed and validated for the clinical market, the benchtop sequencing system will optimize the company’s ability to develop and run diagnostic applications. It enables sample multiplexing, maximizing operator efficiency and increasing throughput.

“The acquisition of this vital piece of technology is a necessary step for us to maintain our commitment to clinical innovation,” said Jim Plante, Pathway Genomics’ founder and CEO.

“The acquisition of this vital piece of technology is a necessary step for us to maintain our commitment to clinical innovation,” said Jim Plante, Pathway Genomics’ founder and CEO.

Continue reading »

Pathway Genomics today announced the launch of Hereditary Colorectal Cancer DNA InsightSM, the company’s premier hereditary cancer genetic test. Based on a simple saliva sample, the test uses next-generation sequencing (NGS) technology to identify gene alterations or mutations that increase a patient’s risk of developing certain types of cancer.

Based on a simple saliva sample, the test uses next-generation sequencing (NGS) technology to identify gene alterations or mutations that increase a patient’s risk of developing certain types of cancer.

Continue reading »

Former senior vice president of business development at Ambry Genetics to drive go-to-market strategies for Pathway Genomics

 

Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services worldwide, today announced it has appointed Ardy Arianpour, MBA, as chief strategy officer. Based at Pathway Genomics’ San Diego headquarters, in this executive management position, Arianpour will spearhead the company’s global strategy, strategic planning, and lucrative partnerships for the company.

“Ardy is an industry expert and a highly respected leader with a wealth of deep experience in the biotechnology and personalized genomics space,” said Jim Plante, Pathway Genomics’ founder and CEO.

“Ardy is an industry expert and a highly respected leader with a wealth of deep experience in the biotechnology and personalized genomics space,” said Jim Plante, Pathway Genomics’ founder and CEO.

Continue reading »

The focus of the discussion was on the preventive aspects of the Affordable Care Act, which includes genetic testing for cancer risk and prevention. As part of Pathway Genomics’ commitment to advancing health care, it plans to offer its cancer panel to physicians at an affordable cost.

This month, Pathway Genomics’ founder and CEO, Jim Plante, attended an exclusive dinner event with President Barack Obama. The focus of the discussion was on the preventive aspects of the Affordable Care Act, which includes genetic testing for cancer risk and prevention. As part of Pathway Genomics’ commitment to advancing health care, it plans to offer its cancer panel to physicians at an affordable cost.

“By offering a comprehensive cancer panel, we are doing our part in helping to reduce the number of cancer victims across the nation – and around the world,” said Plante.

Continue reading »


As one of the sponsors of the event, Pathway Genomics participated in the 2013 Komen San Diego Race for the Cure® 5K.

As one of the sponsors of the event, Pathway Genomics participated in the 2013 Komen San Diego Race for the Cure® 5K.

Susan G. Komen for the Cure is the world’s largest grassroots network of breast cancer survivors and activists fighting to save lives, empower people, ensure quality care for all and energize science to find the cures. The Race for the Cure series raises significant funds and awareness for the breast cancer movement.

Continue reading »

Pathway Genomics Corporation, a San Diego-based CAP-accredited clinical laboratory that offers genetic testing services worldwide, today announced it has received a Clinical Laboratory Permit from the New York State Department of Health. The permit allows authorized health care providers in the state of New York the ability to offer their patients Pathway Fit®, the company’s diet, metabolism, and exercise genetic test.

Considered one of the most rigorous control standards in the country, the validation process required for a New York State Clinical Laboratory Permit is designed to ensure reliable, accurate clinical laboratory services. “Obtaining a New York State Clinical Laboratory Permit is an exciting benchmark in Pathway’s growth and a testament to the quality, reliability and accuracy of Pathway’s services,” said David Becker, Ph.D., Pathway Genomics’ chief scientific officer.

Continue reading »

Pathway Genomics Corporation, a San Diego-based clinical laboratory that offers genetic testing services worldwide, today announced it has appointed Karl Odquist as executive director of managed care. Based at Pathway Genomics’ San Diego headquarters, Odquist will be responsible for managed care contracting, reimbursement, government affairs, and clinical evidence generation for the company’s diagnostic services.

“Karl’s knowledge and experience in coordinating managed care and business development efforts is extensive,” said Jim Plante, Pathway Genomics’ founder and CEO. “His background working with large-scale companies and payers will serve Pathway’s mission in expanding its genetic testing services to a wider network of physicians.”

Continue reading »

Parkway Laboratory Services Ltd to offer Pathway Genomics’ premier nutrigenetic test, Pathway Fit®

Pathway Genomics Corporation, a San Diego-based clinical laboratory that offers genetic testing services internationally, has partnered with Parkway Laboratory Services Ltd, an ancillary service of Parkway Pantai Limited, the largest private healthcare provider in Singapore, and one of the largest private healthcare providers in Asia.

Continue reading »

Pathway Genomics donates money and fifty BRCA1 and BRCA2 breast cancer tests at no charge for patients at high risk

Pathway Genomics and Susan G. Komen, the largest source of nonprofit funds dedicated to the fight against breast cancer, have announced a partnership to educate women about the screening options available to detect a predisposition to breast cancer. In addition to cash donations Pathway Genomics will provide genetic testing to women in need at no charge. The BRCA1 and BRCA2 genes are a component of Pathway Genomics’ comprehensive Hereditary Cancer DNA InsightSM product, currently scheduled for release in August.

Prior to the recent Supreme Court ruling that invalidated certain patent claims covering BRCA1 and BRCA2 genes, testing for risk of breast and ovarian cancers has been unaffordable for many with tests costing as much as $7000. Pathway Genomics’ test will be more accessible and affordable to patients who are at high risk for breast cancer.

Continue reading »

Pathway Genomics announces it will begin offering a BRCA test for breast cancer at a price substantially below the competition

SAN DIEGO (JUNE 14) – Pathway Genomics led the evening news Friday with an announcement that it could begin offering affordable access to genetic testing for the BRCA gene linked to breast and ovarian cancers in the wake of a Supreme Court ruling that eliminated another company’s monopoly on the test.

“These tests, these lifesaving tests will be much more affordable for all of us regardless of how much money is in your pocket.”, Laura Farmer Sherman from the Susan G. Komen chapter told NBC San Diego.

Continue reading »